hkpinoytv, hong kong news, pinoy tv, philippines news, ofw

Update on Dengvaxia Part 1 : More than 800,000 students vaccinated by Dengvaxia vaccine

| December 10, 2017

Update on Dengvaxia Part 1

We at the Department of Health have created a task force for the management of concerns related to the school-based immunization initiative using the tetravalent dengue vaccine. And this is part of the agency’s commitment to closely monitor and attend to the health of those immunized with the vaccine even after this immunization activities were put on hold by us at the DOH last week.

The task force is composed of top management officials of the DOH Central Office and of the affected regions, along with its attached agencies, namely the Food and Drug Administration, PhilHealth, and the National Children’s Hospital. This task force is—this task force rather, will conduct a thorough review of the dengue vaccination initiative which started in March 2016 and the new evidence on safety provided by Sanofi. This shall guide the Department of Health in responding to the safety concerns relevant to the use of this vaccine and how to proceed with the dengue program to ensure safeguards and prevent similar incidents in the future.

We at the DOH reiterate our commitment to heighten surveillance and monitoring activities on all 800,000 students vaccinated with Dengvaxia. We will be hiring 30 additional surveillance officers to be deployed immediately to our hospitals in the four regions where these anti-dengue vaccination activities were conducted.

We will be deploying them immediately for active surveillance and data collection in these hospitals. Surveillance will be done for five years. And this is part of our commitment to the parents and children who were immunized with the anti-dengue vaccines.

The Health department is currently updating the master list of children with—rather given Dengvaxia in coordination with our DOH field offices and the Department of Education. The Task Force on Dengvaxia will have a legal team to look into the accountability of Sanofi Pasteur, the company which marketed Dengvaxia, with an initial claim that the vaccine was safe and effective for all individuals aged 9 to 45 years old.

The French pharmaceutical giant later on acknowledged that the vaccine is not recommended for people who have had no prior dengue infection, lest the vaccination increases the risk of severe dengue, as this disclosure was made only after the Health Department had already vaccinated thousands of school children. And of course, the news, as you are all very much aware of, created a scare among our parents and the Filipino public.

We will demand the refund of the three billion paid for the Dengvaxia and that Sanofi set up an indemnification fund to cover the hospitalization and medical treatment for all children who might have severe dengue.

I also announced that the PhilHealth is ready to cover the expenses of any child who may be hospitalized for severe dengue. PhilHealth’s dengue case rate can cover up to 16,000 for severe dengue, which includes hospitals and physician fees as well as hospital—other hospital support interventions in the management of the dengue cases.

We will continue to be vigilant in monitoring our children for any adverse event following immunization and we will strengthen the readiness of our public hospitals in attending to any severe dengue cases that may occur. Thank you.


Category: Health, News, Sports

Comments are closed.

HKPinoyTV Menu